DrugPatentWatch Database Preview
Abbvie Inc Company Profile
What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?
There are thirty-seven US patents protecting ABBVIE INC drugs.
There are seven hundred and thirty patent family members on ABBVIE INC drugs in sixty-three countries and fifty-six supplementary protection certificates in thirteen countries.
Summary for Abbvie Inc
| International Patents: | 730 |
| US Patents: | 37 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 8 |
| Drug Master File Entries: | 17 |
Drugs and US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | RX | Yes | Yes | 8,642,538 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | RX | Yes | Yes | 8,399,015*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | 8,268,349 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | DISCN | Yes | No | 6,277,405 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,074,670 | ➤ Sign Up |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | 6,037,157 | ➤ Sign Up |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 4,895,726 | ➤ Sign Up |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,277,405 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
Non-Orange Book US Patents for Abbvie Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,343,540 | Process for producing fenofibrate tablets | ➤ Sign Up |
| 9,220,748 | Macrocyclic proline derived HCV serine protease inhibitors | ➤ Sign Up |
| 9,676,797 | Anti-viral compounds | ➤ Sign Up |
| 9,561,181 | Crystal forms | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Abbvie Inc Drugs
Supplementary Protection Certificates for Abbvie Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015011 | Lithuania | ➤ Sign Up | PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115 |
| 2015000039 | Germany | ➤ Sign Up | PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2015011,C2340029 | Lithuania | ➤ Sign Up | PRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
